Trial · NCT03019887
Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
NCT03019887, Not applicable, Completed, Juntendo University; results first posted 2021-09-09
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction. Trials, record NCT03019887. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03019887
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction
- NCT number
- NCT03019887
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 139 participants, actual
- Lead sponsor
- Juntendo University
- Conditions
- Schizophrenia Relapse
- Interventions
- reduction of risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine
- First posted
- 2017-01-13
- Last updated
- 2021-09-09
- Results first posted
- 2021-09-09
Source ClinicalTrials.gov
Registered outcomes1
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Relapse | One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first. | The definition of relapse is as follows 1.50% or greater increase in total DIEPSS score, 2. an increase in the total PANSS score of 25% or more from baseline, 3. deliberate self-injury, 4. emergence of clinically significant suicidal ideation, 5. violent behavior resulting in clinically significant injury to another person or property damage. |
Source ClinicalTrials.gov
Outcomes1
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Relapse | One year after the baseline cognitive function test or three months after the end of dose reduction, whichever came first. | patients with schizophrenia taking more than 1000 mg / day of antipsychotics, reduce their dose to less than 1000 mg | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group1
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Relapse | Dose Reduction | 130 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Dose Reduction | 139 | |
| Overall Study | COMPLETED | Dose Reduction | 130 | |
| Overall Study | NOT COMPLETED | Dose Reduction | 9 |
Source ClinicalTrials.gov
Adverse events3
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | increase in the total PANSS score from baseline | Psychiatric disorders | Dose Reduction | 51 | 130 | |
| other | increase in total DIEPSS score | Psychiatric disorders | Dose Reduction | 0 | 130 | |
| other | violent behavior | Psychiatric disorders | Dose Reduction | 15 | 130 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Dose Reduction | ||
| Total, other adverse events | Dose Reduction | 51 | 130 |
| Total, serious adverse events | Dose Reduction | 0 | 130 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03019887
GET https://conductscience.org/api/trials/v1/NCT03019887/registered